Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Prospective Study of End Stage Renal Disease Patients With Coronary Artery Disease Treated by Oral Nicorandil

This study is ongoing, but not recruiting participants.
Information provided by (Responsible Party):
Yasuhiro Nagayoshi, Kumamoto University Identifier:
First received: November 16, 2011
Last updated: March 2, 2017
Last verified: March 2017
Nicorandil is potentially effective to prevent cardiovascular events in patients with coronary artery disease (CAD) receiving hemodialysis. The purpose of this study is to prospectively investigate whether nicorandil is effective in reducing the incidence of cardiovascular events in patients with CAD on hemodialysis.

Condition Intervention Phase
Coronary Artery Disease
End Stage Renal Disease
Drug: Nicorandil
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: No masking
Primary Purpose: Prevention
Official Title: Effects of Nicorandil on Cardiovascular Events in Patients With Coronary Artery Disease Receiving Hemodialysis

Resource links provided by NLM:

Further study details as provided by Kumamoto University:

Primary Outcome Measures:
  • The primary endpoint is composite of :1) cardiovascular death 2)sudden cardiac death 3)nonfatal myocardial infarction 4)Hospitalization for recurrent symptomatic myocardial ischemia 5)stroke [ Time Frame: 2 years ]

Secondary Outcome Measures:
  • Total mortality [ Time Frame: 2 years ]
  • revascularization therapy [ Time Frame: 2 years ]
  • hospitalization for heart failure [ Time Frame: 2 years ]
  • hospitalization for peripheral artery disease [ Time Frame: 2 years ]
  • newly onset of atrial fibrillation [ Time Frame: 2 years ]

Enrollment: 268
Study Start Date: June 2008
Estimated Study Completion Date: December 2017
Primary Completion Date: June 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Nicorandil
Nicorandil was administered orally (15mg/day).
Drug: Nicorandil
15mg per day
Other Name: Sigmart
No Intervention: Non-nicorandil
Nicorandil was not administered.

Detailed Description:

Patients on hemodialysis for end-stage renal disease are at high risk for death from ischemic heart disease. It was reported that nicorandil, a hybrid compound on adenosine triphosphate-sensitive potassium channel opener and nitric oxide door, was potentially effective to prevent cardiovascular events in patients with CAD receiving hemodialysis. Therefore, investigators prospectively examine whether nicorandil is effective in reducing the incidence of cardiovascular events in patients with CAD on hemodialysis.

The primary endpoint is a composite of cardiovascular death, sudden cardiac death, nonfatal myocardial infarction, hospitalization for recurrent symptomatic myocardial ischemia and stroke. The secondary endpoints are total mortality, revascularization therapy, hospitalization for heart failure, hospitalization for peripheral artery disease and newly onset of atrial fibrillation.

Patient population that needs to prove the hypothesis is estimate to be 300 cases in total (150 cases in each group). Investigators set the parameters which are need to calculate the number of study patients as follows; drop out rate 10%, an event rate of the primary end point for two years 50%, a risk reduction rate brought by nicorandil 60%, a statistical power 80% and two-sided significant level 0.05. Investigators referred the event rate and the risk reduction rate from the previous study by Ishi H et al. In this study, event rate of the primary end point for two years was 50% and the risk reduction brought by nicorandil was 60%. Event rate of the present study will be lower, because drug-eluting stents are widely used to prevent restenosis in the present era. Moreover, investigators include the patients underwent coronary bypass graft in the present study. In addition, non-cardiovascular mortality is high in the patients on hemodialysis. Considering all the various factors together, investigators estimated the study sample size.


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

Eligible patients are who meet the following criteria:

  • Patient with previously diagnosed coronary artery disease (significant coronary artery stenosis is defined as > 75% narrowing of the artery lumen)
  • Patients who continued hemodialysis for more than one month

Exclusion Criteria:

  • Within one month after acute myocardial infarction
  • Within 3 months after coronary artery bypass graft (CABG)
  • Treatment with phosphodiesterase type 5 inhibitor
  • Candidates for carotid artery stenting
  • Severe disease requiring active medical treatment
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01475123

Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University
Kumamoto, Japan, 860-8556
Sponsors and Collaborators
Kumamoto University
Study Chair: Hisao Ogawa, MD, PhD Kumamoto University
  More Information

Responsible Party: Yasuhiro Nagayoshi, principal investigator, Kumamoto University Identifier: NCT01475123     History of Changes
Other Study ID Numbers: CVM-2008-PRECON
Study First Received: November 16, 2011
Last Updated: March 2, 2017
Individual Participant Data  
Plan to Share IPD: Undecided

Keywords provided by Kumamoto University:
Randomized control study
Coronary Artery Disease

Additional relevant MeSH terms:
Coronary Artery Disease
Myocardial Ischemia
Coronary Disease
Kidney Diseases
Kidney Failure, Chronic
Renal Insufficiency, Chronic
Heart Diseases
Cardiovascular Diseases
Arterial Occlusive Diseases
Vascular Diseases
Urologic Diseases
Renal Insufficiency
Anti-Arrhythmia Agents
Antihypertensive Agents
Vasodilator Agents
Vitamin B Complex
Growth Substances
Physiological Effects of Drugs processed this record on May 25, 2017